# Shawnte Mitchell

Type: Person

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/shawnte-mitchell
Canonical HTML page: https://getfinancebrief.com/entity/shawnte-mitchell

## Timeline

- **2027 (projected)**: Commercial Launch — Target date for the market entry of palazestrant for ER+ breast cancer treatment.
- **2026-03-22**: Institutional Stake Disclosure — Reports surfaced regarding a significant $122 million position held by a major investor.
- **2026-03-20**: Price Target Hike — Wall Street analysts raised the price target for OLMA to $62.00, citing clinical optimism.
- **2026-03-16**: Earnings & SEC Filing — Olema reported quarterly results and filed an 8-K detailing its financial condition.

## Recent coverage (1 stories)

### Olema Pharmaceuticals Surges 242% as $122M Institutional Stake Signals Growth
2026-03-22 19:19:48 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Olema Pharmaceuticals (OLMA) has delivered a massive 242% return over the past year, fueled by clinical progress in its lead breast cancer candidate, palazestrant. A recent $122 million institutional position has sparked debate over whether the biotech firm still has significant room for growth ahead of a projected 2027 launch.
Full story: https://getfinancebrief.com/story/olema-pharmaceuticals-stock-surge-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.